MOWOOT’s Post

🌟 Empowering Innovation with BioMan4R2! 🌟 ⏩ Check out our #10 Success Story! 🏅 IntegraSkin (ISK) was one of the awarded companies within the 𝙄𝙉𝙉𝙊𝙑𝘼𝙏𝙄𝙊𝙉 𝙁𝙄𝙉𝘼𝙉𝘾𝙄𝘼𝙇 𝙎𝙐𝙋𝙋𝙊𝙍𝙏 category. IntegraSkin specializes in personalized therapy optimization for patients with Chronic Inflammatory Skin Conditions (CISCs). Leveraging advanced laboratory and molecular testing combined with AI and environmental monitoring through their #KiDERM platform, ISK identifies the unique factors influencing each patient's condition. This approach enhances diagnostic accuracy, boosts treatment effectiveness, and lowers healthcare costs and the risk of side effects. 🗣 “𝘉𝘪𝘰𝘔𝘢𝘯4𝘙2 𝘧𝘰𝘴𝘵𝘦𝘳𝘴 𝘢 𝘩𝘦𝘢𝘭𝘵𝘩𝘺 𝘳𝘪𝘴𝘬-𝘵𝘢𝘬𝘪𝘯𝘨 𝘮𝘦𝘯𝘵𝘢𝘭𝘪𝘵𝘺 𝘵𝘩𝘢𝘵'𝘴 𝘰𝘧𝘵𝘦𝘯 𝘮𝘪𝘴𝘴𝘪𝘯𝘨 𝘪𝘯 𝘌𝘶𝘳𝘰𝘱𝘦. 𝘉𝘺 𝘱𝘳𝘰𝘷𝘪𝘥𝘪𝘯𝘨 𝘵𝘩𝘦 𝘤𝘳𝘶𝘤𝘪𝘢𝘭 𝘭𝘦𝘢𝘱 𝘰𝘧 𝘧𝘢𝘪𝘵𝘩 𝘢𝘯𝘥 𝘳𝘦𝘴𝘰𝘶𝘳𝘤𝘦𝘴 𝘦𝘢𝘳𝘭𝘺-𝘴𝘵𝘢𝘨𝘦 𝘤𝘰𝘮𝘱𝘢𝘯𝘪𝘦𝘴 𝘯𝘦𝘦𝘥, 𝘪𝘵 𝘦𝘯𝘢𝘣𝘭𝘦𝘴 𝘵𝘩𝘦𝘮 𝘵𝘰 𝘵𝘦𝘴𝘵 𝘢𝘯𝘥 𝘳𝘦𝘧𝘪𝘯𝘦 𝘵𝘩𝘦𝘪𝘳 𝘮𝘰𝘥𝘦𝘭𝘴 𝘣𝘦𝘧𝘰𝘳𝘦 𝘴𝘦𝘦𝘬𝘪𝘯𝘨 𝘮𝘢𝘫𝘰𝘳 𝘪𝘯𝘷𝘦𝘴𝘵𝘮𝘦𝘯𝘵. 𝘉𝘪𝘰𝘔𝘢𝘯4𝘙2 𝘪𝘴 𝘢 𝘷𝘪𝘵𝘢𝘭 𝘦𝘹𝘢𝘮𝘱𝘭𝘦 𝘰𝘧 𝘣𝘳𝘦𝘢𝘬𝘪𝘯𝘨 𝘵𝘩𝘦 𝘧𝘶𝘯𝘥𝘪𝘯𝘨 𝘤𝘺𝘤𝘭𝘦 𝘵𝘩𝘢𝘵 𝘴𝘵𝘪𝘧𝘭𝘦𝘴 𝘌𝘶𝘳𝘰𝘱𝘦𝘢𝘯 𝘪𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘰𝘯, 𝘱𝘢𝘷𝘪𝘯𝘨 𝘵𝘩𝘦 𝘸𝘢𝘺 𝘧𝘰𝘳 𝘨𝘳𝘰𝘶𝘯𝘥𝘣𝘳𝘦𝘢𝘬𝘪𝘯𝘨 𝘢𝘥𝘷𝘢𝘯𝘤𝘦𝘮𝘦𝘯𝘵𝘴.”, a company representative says. 👉 Project Focus: #KiDERM This project targets the regulatory, economic, and market entry challenges for Ki-DERM. Key objectives include: ✅ Regulatory Compliance: Achieving necessary certifications to ensure compliance. ✅Market Prospects: Enhancing sales potential and attracting venture capital investments. ✅Grant Applications: Securing successful grant funding. 🎉Congratulations IntegraSkin on your achievements! 🎉 Vladimir Andrey Giménez Rivera Ph.D. #resilience #europeanunion #medicaldevice #EUfunding #medtech #cascadefunding #germany #Innovation #Startups #Funding #Biotech #Entrepreneurship #EuropeanInnovation #BioMan4R2 #BadenWürttemberg Turku Science Park Ltd Council of European BioRegions - CEBR Biocat, BioRegion of Catalonia BioRegio STERN Management GmbH MedSilesia Cluster - Silesian Medical Devices Network Upper Silesian Accelerator For Commercial Enterprises Medicen Paris Region LifetecZONe

We're proud to be a #mediapartner of the LSX World Congress — Connecting #Innovation with #Capital. The #event takes place from 29–30 April in London, with 2000+ attendees joining. The 10th LSX World Congress gathers the founders and CEOs of innovative #biotech, #medtech and #healthtech #startups through to healthcare giants, and everyone in between. They attend alongside the sector’s most active #investors, #pharma, medtech and healthtech BD&L teams and R&D leaders. #LSXWorld brings together the people who are developing technologies, solutions and new business models to tackle the biggest healthcare challenges in the industry today, and helps answer the question; what’s next and how do we get there? Find out more 👉 https://lnkd.in/ddbtpquX LSX - partnering for Life Science eXecutives #messengersinscience

🌍💡 Introducing Genomac Innovation Hub (G-iHub): Powering the Future of Health Tech and Beyond! Genomac Innovation Hub (G-iHub), a cutting-edge platform dedicated to driving innovation, development, and commercialization across the health tech and broader technological sectors. As a subsidiary of Genomac Holdings, G-iHub is committed to transforming groundbreaking ideas into market-ready products that improve lives and stimulate economic growth. 🌟 Our Mission: To lead with landmark achievements, turning creativity into real-world solutions that make a lasting impact. 🌐 Our Portfolio: Health tech products, startup incubation, interdisciplinary research, and more—focused on creating significant social and economic outcomes. At G-iHub, we foster collaboration, champion sustainability, and deliver innovation that truly matters. Let’s reshape the future together! #GenomacInnovationHub #Gihub #GenomacHoldings #HealthTech #InnovationInScience #Biotechnology #Biotech

🌟 Biolevate is thrilled to be part of the #Future40 at STATION F! 🌟 We’re excited to announce that Biolevate has been selected as one of the Future 40 startups at STATION F, the world’s largest startup campus. This recognition places us among the top 4% of over 1,000 startups, reaffirming our mission to bring biotechnology-driven solutions to life. 🌱 In the past decade, FDA submissions for therapeutic products have doubled, signaling remarkable progress in healthcare innovation. However, this ray of hope is often overshadowed by significant challenges in bringing these therapies to market: 🔵 Medications can take up to 15 years to reach patients. 🔵 90% of biotech and research initiatives falter due to regulatory hurdles. 🔵 Even effective treatments sometimes miss critical authorization renewals. At Biolevate, we know there’s a faster, smarter way forward. That’s why we created ELISE—a platform designed by a team of AI and healthcare veterans to transform the market access process. Our platform is built to be: ✅ 100% explainable ✅ 100% teachable ✅ 100% collaborative In just 9 months, we’ve achieved remarkable results: 👉 We reduced the time required for each critical step by threefold. 🏥Patients are waiting, and the future of healthcare can’t wait. Our mission is to bring their hopes to market faster, transparently, and sustainably. A huge thank you to our amazing team, partners, clients, and the STATION F community for believing in us. Together, we’re building a future where biotechnology brings meaningful impact to those who need it most. 👉 Learn more about Biolevate and our vision: https://lnkd.in/gxCNRrAP 🌐 Photo © Elliot Aubin #Future40 #Biolevate #Innovation #STATIONF #Biotechnology #Sustainability #HealthcareInnovation #TechForGood

More from Nutromics at the Life Science Intelligence (LSI) USA conference last month in California! In addition to his presentation on our breakthrough DNA-based sensor technology, CEO Peter Vranes was invited to participate in a panel discussion titled "The Future of Device-Driven Data: Delivering Real Insights and Outcomes From Mountains of Information". This is an important topic for Nutromics, as our platform will provide clinicians with continuous and real-time diagnostic insights, allowing them to make more informed decisions. It was great to share the stage and learn more about the power of device-driven data and its impacts on health with BrainSpace CEO Caitlin Morse, Windham Venture Partners Managing Partner David Kereiakes, Cure Capital Advisors CEO David Cubbin, and Trinity Life Sciences Managing Director Deepak Sahu, who moderated the discussion! The future of MedTech is nothing short of exciting! . . . #medtech #healthtech #data #devicedata #medicaldevices #lsiusa24 #lsi24 #lifesciences #lifescienceintelligence #nutromics #startup #medtechstartup #scaleup #research #science #healthtech #healthcare

As promised, I'm starting with some very interesting life-science- and biotech startups. Starting with AdRegeneer. 🚀 Revolutionizing Regenerative Medicine: Meet AdRegeneer! Have you ever wondered what it takes to truly transform the field of regenerative medicine? AdRegeneer is doing just that, and their journey is nothing short of inspiring. At #Curious2024, I had the pleasure of meeting the brilliant minds behind AdRegeneer, a startup dedicated to filling a critical void in the medical landscape. Their mission? To provide innovative treatments that promote axonal regrowth and remyelination – therapies that are currently unavailable elsewhere. Imagine a world where nervous system injuries and disorders are no longer a life sentence. AdRegeneer is making this a reality with their groundbreaking research and cutting-edge solutions. Read the full post and see the video here: Mert Duman

Verve Ventures was recently featured among the top techbio and drug discovery investors in Dealroom.co and Speedinvest's TechBio x Drug Discovery report which explores the vast potential of innovation in this field. “We believe that startups embracing the convergence of biology and engineering have the power to shape a future where healthcare is not only more cost-effective but also delivers superior patient outcomes,” says Xavier Mesnier, Principal at Verve. “Through AI-driven patient profiling, platform technologies, and enabling tools, techbio entrepreneurs are catalyzing a paradigm shift in healthcare, where data-driven insights revolutionize how we understand and combat disease." Read the full report: https://lnkd.in/d9BcvV2Q #techbio #drugdiscovery #health #drugdevelopment #futureofhealth #venturecapital

🚀 3 Tips to Stay Ahead in Biotech in the Healthcare Sector In the rapidly evolving world of biotech, staying ahead of the curve is crucial. Here are three essential tips to ensure you remain at the forefront of innovation: 1 - Embrace Innovation 🧬💡 2 - Focus on Robust Clinical Trials 📊✅ 3 - Build Strong Collaborations 🤝🌍 These insights come from our recent interview with Megan Baldwin, Founder and Chief Innovation Officer at Opthea. Click the link below to watch the full interview and gain more valuable insights: 🔗👉 https://lnkd.in/dSs2kzpC . . . #Biotech #Innovation #Healthcare #ClinicalTrials

🎤 Today, we have the pleasure of featuring Dr Kieran Mulroney, CEO and founder of Cytophenix (CUREator Health Security Stream) and his team.   🚀 The Cytophenix Mission: We spun out of The University of Western Australia in 2023 with a clear mission—to help doctors get the right antibiotic to the right patient faster while preserving the most potent antibiotics for future use. Our diagnostic test improves individual patient outcomes and supports global antimicrobial stewardship, an increasingly urgent need in the face of antimicrobial resistance (AMR).   💡 What Inspired Cytophenix: Our tech came from academic insights, where we saw the potential to drastically improve clinical decision-making by speeding up the process of getting doctors the information they need. With AMR making treatment decisions harder, getting the right test results faster is essential.   🎯 Why We Applied For CUREator: Our technology was at a critical stage of development. We needed to refine our Artificial Intelligence (AI) software, automate analysis, and test an end-to-end prototype. The CUREator program came at just the right time, helping us field-test our product, develop regulatory strategies, and set the foundation for market entry.   📈 How We've Grown: The CUREator program helped us spin out of UWA and really accelerate our commercialisation efforts. With follow-on funding and further support from programs like CSIRO ON, we’re preparing for regulatory approval and engaging investors as we move toward our next big milestones.   💬 Advice for Biotech Startups: Joining an incubator like CUREator is just the start. Keep testing your ideas, talking to stakeholders, and evolving as you go. And remember—it takes a village to build something meaningful.   Congratulations to the talented Cytophenix team! Christine Carson Sherief Khorshid Teagan Paton Nick Thomson #CUREator #HealthSecurity #Biotech #Innovation #AntimicrobialResistance #Healthcare #Startups #Cytophenix #PatientCare

One day left to register for the webinar to learn how – and when – to define your regulatory strategy to ensure your next women’s health innovation is a success. Robin Stephens, Psephos Biomedica and Erica Kantor, Sagentia Innovation will discuss: - The emerging women’s health technology landscape - The challenges women’s health start-ups face when developing and commercialising new solutions - The pros and cons of the direct-to-consumer approach, vs seeking regulatory approval - The key considerations in developing a successful commercialisation strategy Register here: https://lnkd.in/efEKZUw8 Science & Engineering Health Technologies Alliance (SEHTA) #WomensHealth #Regulatory #MedTech